Boston Scientific said it has obtained FDA approval for its Taxus Atom, a drug-coated stent aimed at treating coronary artery disease in small blood vessels. The agency also granted the company approval to expand the use of its Taxus stent for the treatment of scar tissue in vessels of patients who received a bare-metal stent. The clearances indicate that Boston Scientific is "making progress" in resolving quality issues mentioned in an FDA warning letter, CEO James Tobin said.

Related Summaries